hDMT Organ-on-Chip Consortium
Jetty van Ginkel is an experienced professional in the biomedical and health innovation sectors, currently serving as Managing Director and Board Member at hDMT since August 2025. Prior to this, Jetty van Ginkel was the Owner of Care for IMPACT and held significant roles such as Business Director at CareTech and Mentor at the University Industry Innovation Network. Contributions include establishing and coordinating research networks in urology at NVU Urologie, and leading business development efforts at Erasmus MC. Jetty van Ginkel's academic background includes a PhD in Bionanoscience from TU Delft and degrees in Biomedical Engineering from the University of Twente.
This person is not in any teams
This person is not in any offices
hDMT Organ-on-Chip Consortium
hDMT is a consortium of renowned scientists from the fields of engineering, biology, physics, chemistry, pharmacology and medicine. They share knowledge, expertise and facilities to develop organ-on-chip models, by integrating state-of-the-art human stem cell technologies and top level engineering with a wide variety of other disciplines. hDMT is a pre-competitive, non-profit technological R&D institute. hDMT researchers work in academic research institutions, university medical centers and biotechnology companies in the Netherlands. Its partners refer to hDMT as ‘a laboratory without walls’. hDMT aims to disseminate models and data through open access publication and valorisation. HDMT’S OBJECTIVE To develop validated cultured cell models of healthy and diseased human tissues and organs through organ-on-chip technology, and enable their valorisation, implementation and availability to interested users for a wide variety of applications. An advantage of this technology could be the reduction of animal experiments.